MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2017 International Congress

    Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

    H. Todo (Sanda, Japan)

    Objective: To examine long-term effect of botulinum toxin injection (BTX) in the external oblique muscle (EO) for camptocormia associated with Parkinson’s disease (PD). Background: Camptocormia…
  • 2017 International Congress

    Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial

    M. Jog, J. Lee, M. Althaus, A. Scheschonka, H. Dersch, E.T. Study Team, D. Simpson (London, ON, Canada)

    Objective: To demonstrate improvement of arm tremor severity and hand function with kinematics-guided inco/A therapy Background: Botulinum neurotoxin A (BoNT-A) therapy of debilitating tremor symptoms…
  • 2017 International Congress

    Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm

    A. Wagle Shukla, J. Legacy, W. Deeb, W. Hu (Gainesville, FL, USA)

    Objective: To determine whether repetitive transcranial magnetic stimulation (rTMS) of anterior cingulate cortex (ACC) when added to botulinum toxin (BoNT) therapy improves benign essential blepharospasm…
  • 2017 International Congress

    Differences between Hemifacial spasm with or without neurovascular conflict. Therapeutic implications with botulinum toxin type A.

    J.S. Bestoso, L. Ciancaglini, C. Stefani, C. Azcona, M.L. Contartese, A. Pappolla, J.I. Rojas, D. Bauso (Buenos Aires, Argentina)

    Objective: To evaluate the presence of possible clinical differences between patients with HS with and without neurovascular conflict (NVC +, NVC-) and their therapeutic response…
  • 2017 International Congress

    Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

    R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

    Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…
  • 2017 International Congress

    Palmaris Brevis Spasm:A rare cause of paediatric movement disorder

    T. Yeo, A. Yacoob (Singapore, Singapore)

    Objective: Case report of paediatric Palmaris Brevis Spasm (PBS) Background: PBS is a rare movement disorder causing intermittent twitching of the palmaris brevis muscle. This muscle…
  • 2017 International Congress

    Saliva changes and the oral health in Parkinson´s disease

    J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)

    Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…
  • 2017 International Congress

    A double-blind, randomized, placebo controlled study of botulinum toxin type A for limb pain in advanced Parkinson’s disease

    V. Bruno, M. Freitas, D. Mancini, J. Liu, J. Miyasaki, S. Fox (CABA, Argentina)

    Objective: To evaluate safety, tolerability and efficacy of botulinum toxin type A for limb pain in advanced Parkinson´s disease (PD). Background: Pain is a frequent…
  • 2017 International Congress

    Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm

    S. Pandey, S. Jain (New Delhi, India)

    Objective: To study demographic and clinical features of  primary and secondary hemifacial spasm and assess their response to botulinum toxin therapy. Background: Hemifacial spasm (HFS)…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley